Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Streptomycin as second-line chemotherapy for tuberculosis].

P Ruiz1, F Rodríguez-Cano, F J Zerolo

  • 1Centro de Referencia de Micobacterias, Facultad de Medicina, Universidad de Cordoba, Cordoba, Spain. mi1carom@uco.es

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|September 16, 2003
PubMed
Summary

Streptomycin, an early tuberculosis antibiotic, shows renewed promise despite resistance concerns. Studies found low secondary resistance rates (2.1%) in Mycobacterium tuberculosis strains, indicating potential for current use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural characterization of the <i>Aspergillus niger</i> citrate transporter CexA uncovers the role of key residues S75, R192 and Q196.

Computational and structural biotechnology journal·2023
Same author

Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy.

Medical oncology (Northwood, London, England)·2022
Same author

Membrane transporters in the bioproduction of organic acids: state of the art and future perspectives for industrial applications.

FEMS microbiology letters·2020
Same author

Production of bioactive hepcidin by recombinant DNA tagging with an elastin-like recombinamer.

New biotechnology·2018
Same author

In vitro studies of DNA damage and repair mechanisms induced by BNCT in a poorly differentiated thyroid carcinoma cell line.

Radiation and environmental biophysics·2018
Same author

Canine GM2-Gangliosidosis Sandhoff Disease Associated with a 3-Base Pair Deletion in the HEXB Gene.

Journal of veterinary internal medicine·2017

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Streptomycin was the first antibiotic for Mycobacterium tuberculosis (M. tuberculosis) treatment.
  • Historical monotherapy use led to resistance, reducing its clinical application.
  • Rising drug resistance necessitates re-evaluating older antibiotics like streptomycin.

Purpose of the Study:

  • To assess the current efficacy and resistance patterns of streptomycin against M. tuberculosis.
  • To understand the prevalence of streptomycin resistance in clinical isolates.

Main Methods:

  • Analysis of streptomycin susceptibility in 899 M. tuberculosis isolates (713 pulmonary, 186 extrapulmonary).
  • Utilized BACTEC 460 TB and ESP II systems for drug susceptibility testing.

Related Experiment Videos

  • Employed ATCC27294 as a control strain for streptomycin, rifampicin, ethambutol, and isoniazid.

    • Main Results:

    • A low rate of secondary resistance to streptomycin was observed (2.1%) across all tested strains.
    • Multidrug resistance was identified in 12 of the M. tuberculosis isolates.
    • Pulmonary and extrapulmonary isolates showed comparable resistance profiles.

    Conclusions:

    • Streptomycin retains potential utility against M. tuberculosis, with a low incidence of secondary resistance.
    • Monitoring resistance mechanisms, including mutations in rRNA 16S and protein S12, is crucial.
    • Further research into optimized streptomycin regimens is warranted given current resistance challenges.